Evidence map›Paper›PMID 33075521›Full record

ArticleJournal of global antimicrobial resistance2020

Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.

Andrea Ciorba, Piotr Henryk Skarżyński, Stefano Pelucchi, Stavros Hatzopoulos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global antimicrobial resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. SARS-CoV-2 (COVID-19) and audio-vestibular disorders.International journal of immunopathology and pharmacology
    Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Andrea CiorbaENT & Audiology Department, University Hospital of Ferrara, Cona, Italy. Electronic address: andrea.ciorba@unife.it.
Piotr Henryk SkarżyńskiInstitute of Physiology and Pathology of Hearing, Warsaw, Poland; Department of Heart Failure and Cardiac Rehabilitation, Medical University of Warsaw, Warsaw, Poland; Institute of Sensory Organs, Kajetany, Poland.
Stefano PelucchiENT & Audiology Department, University Hospital of Ferrara, Cona, Italy.
Stavros HatzopoulosENT & Audiology Department, University Hospital of Ferrara, Cona, Italy.
University of Ferrara · ITInstitute of Physiology and Pathology of Hearing · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim of this paper is to remind the risk of ototoxicity when using chloroquine and hydroxychloroquine, in particular as prophylactic agents against SARS-CoV-2, during the pandemic. Healthy subjects taking chloroquine and hydroxychloroquine as prophylactic agents against SARS-CoV-2, during the pandemic, should be screened periodically, at least by Otoacoustic Emissions (OAEs) in order to detect early manifestations of possible cochlear ototoxic damages.

Indexed as

COVID-19 Drug TreatmentAntiviral AgentsChloroquineHumansHydroxychloroquineOtotoxicityPandemicsRisk AssessmentSARS-CoV-2Antiviral AgentsChloroquineHydroxychloroquineChloroquineHydroxychloroquineOtotoxicityPreventionSARS-CoV-2 (Covid-19)

Identifiers

PMID33075521
PMCPMC7568171
OpenAlexW3093054458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.